Abstract P4-04-31: A phase Ib/II study of PARPi Mefuparib Hydrochloride (CVL218) in combination with PD-1 inhibitor plus chemotherapy in metastatic or recurrent triple-negative breast cancer (TNBC)

三阴性乳腺癌 医学 化疗 转移性乳腺癌 癌症 三重阴性 乳腺癌 临床研究阶段 内科学 肿瘤科 癌症研究
作者
Jian Zhang,Rujiao Liu
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (12_Supplement): P4-04
标识
DOI:10.1158/1557-3265.sabcs24-p4-04-31
摘要

Abstract Background: Triple-negative (negative for human epidermal growth factor receptor 2 [HER2] and estrogen and progesterone receptors) breast cancer (TNBC) is the breast cancer subtype with the worst prognosis. It represents approximately 15% -20% of all breast cancer cases. BRCA 1 and /or BRAC 2 mutation accounts for about 15% of all TNBC and remains poor outcomes for such patients. TORCHLIGHT trial is a randomized, double-blinded, phase 3 study assesses the efficacy and safety of toripalimab (programmed cell death-1 inhibitor) combined with nab-paclitaxel (nab-P) as a first-line treatment for patients diagnosed with metastatic or recurrent TNBC. The (progression-free survival) PFS and (overall survival) OS analysis, showed a significant improvement in PD-L1 positive (CPS ≥ 1) tumors. Phase III OlympiAD study has established the efficacy of Poly ADP-ribose polymerase inhibitors (PARPi) olaparib in patients with germline BRCA gene mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer. Mefuparib hydrochloride (CVL218) is a second generation of PARPi with low hematological toxicity and the ability to cross the blood-brain barrier. The major purpose of this study is to explore the RP2D, efficacy and safety of CVL218 combined with PD-1 inhibitors and paclitaxel nanoparticle albumin-bound in patients with TNBC who have failed previous first-line treatment. The second endpoint of this study is to analyze the efficacy of each subgroup according to PD-L1 expression and HRD (Homologous Recombination Deficiency) mutation status. Methods: This open- labeled, phase Ib/II clinical study was conducted in China. In phase Ib, the “3+3” principle is used to explore the RP2D of CVL218. Two dose escalation of CVL218 were preset, which are 500mg twice daily (BID) and 700mg BID. CVL218 administered orally in combination with toripalimab 240 mg on Day 1 of every 21-day cycle and paclitaxel nanoparticle albumin-bound 125 mg/m2 on Day 1 of every 21-day cycle. The first cycle (21 days) after administration was also defined as the DLT (dose-limiting toxicity) observation period. At last, no DLT was observed in the 3 evaluable subjects in the CVL218 500 mg BID dose group, and DLT was observed in 2 evaluable subjects in the 700 mg BID dose group, including creatinine increased and aspartate aminotransferase, Alanine aminotransferase increased. Therefore, the RP2D was determined as 500 mg BID. Patients in phase II cohort A were advanced TNBC with either CPS ≥ 1 or HRD gene pathogenic variants. All these patients received CVL218 (500mg BID) + toripalimab (240 mg) + paclitaxel nanoparticle albumin-bound (125 mg/m2, ). Results: From July 2023 to 15 July 2024 data, a total of 6 subjects were enrolled in Phase Ib and 5 subjects were enrolled in Phase II. The median age of the 11 subjects was 55.2 years. In phase Ib, The RP2D of CVL218 was identified as 500 mg BID. The preliminary efficacy was perfomed every 6 weeks in the first half a year and then once every 12 weeks thereafter in both phase I and II according to RECISTv 1.1. Among 11 patients, ORR (Objective Respond Rate) was 72.7% (8 PR, 2 SD), and DCR (Disease Control Rate) was 90.9%. The most common Grade 3 or higher treatment-related AEs (TRAEs) were hepatic function injury (2.6%), adynamia (1.8%), creatinine increased (0.8%), neutrophils decreased (0.8%), white blood cell decreased (0.8%), exanthema (0.8%), and peripheral sensory nerve disorder (0.8%), No Grade 5 TRAE. A total of 9 treatment-related SAEs in 6 patients (54.5%) were observed, including 2 aspartate aminotransferase increased, 2 alanine aminotransferase increased, 1 creatinine increased, 1 liver function injury, 1 adynamia, 1 neutrophils decreased, 1 fever, and 1 ventricular premature beats. All these SAEs recovered after symptomatic treatment. Conclusion: Mefuparib Hydrochloride(CVL218) combined with PD-1 and chemotherapy appears to be well tolerated and has preliminary efficacy in TNBC patients. In this phase II study, stratified analyses will be conducted for PD-L1 expression and HRD status. In patients with BRCA 1 and /or BRAC 2 mutation TNBC, this CVL218 combination therapy is expected to further break through the clinical treatment effect. Citation Format: Jian Zhang, Rujiao Liu. A phase Ib/II study of PARPi Mefuparib Hydrochloride (CVL218) in combination with PD-1 inhibitor plus chemotherapy in metastatic or recurrent triple-negative breast cancer (TNBC) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P4-04-31.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ysgzg20123完成签到,获得积分10
刚刚
yao完成签到,获得积分10
1秒前
1秒前
1秒前
科研通AI2S的应助被咻咻咻采纳,获得10
1秒前
Maestro_S的应助被yh采纳,获得10
1秒前
安安完成签到 ,获得积分10
1秒前
科研通AI6.3的应助被yh采纳,获得10
2秒前
2秒前
pkfsp发布了新的文献求助10
3秒前
z66完成签到,获得积分10
3秒前
可爱的蓝天完成签到 ,获得积分10
3秒前
4秒前
4秒前
Noreason完成签到 ,获得积分10
4秒前
顾矜的应助被51515采纳,获得10
5秒前
5秒前
wenlin完成签到,获得积分10
6秒前
西大可怜虫完成签到,获得积分10
6秒前
7秒前
xixi发布了新的文献求助10
7秒前
wyp给张临秋的求助进行了留言
8秒前
香蕉觅云的应助被Bai采纳,获得10
8秒前
keggin发布了新的文献求助10
8秒前
9秒前
捡破烂的发布了新的文献求助10
10秒前
10秒前
天天快乐的应助被粗暴的依波采纳,获得20
11秒前
zrl完成签到,获得积分20
12秒前
12秒前
Jasper的应助被TFoCR7采纳,获得10
13秒前
科研通AI2S的应助被科研通管家采纳,获得10
13秒前
lx的应助被科研通管家采纳,获得10
13秒前
13秒前
Shelley发布了新的文献求助10
13秒前
14秒前
丘比特的应助被科研通管家采纳,获得10
14秒前
秋风的应助被橘子采纳,获得10
14秒前
充电宝的应助被科研通管家采纳,获得30
14秒前
乐空思的应助被科研通管家采纳,获得30
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178695
求助须知:如何正确求助?哪些是违规求助? 9569449
关于积分的说明 21804643
捐赠科研通 7773744
什么是DOI,文献DOI怎么找? 3432903
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478500